Inflammatory optic neuritis;Neuritis óptica inflamatoria

Anales del Sistema Sanitario de Navarra

Volumn 32, Issue 2, 2009, Pages 249-263

  Ayuso Blanco, Teresa ^a   Aliseda, D ^a   Ajuria, I ^a   Zandio B ^a   Mayor, S ^a   Navarro, M C ^a  

^a Universidad Pública de Navarra   (Spain)

Author keywords

Bilateral optic neuritis; Inflammatory optic neuritis; Isolated clinical syndrome; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; BIOLOGICAL MARKER; CORTICOSTEROID; GLATIRAMER; PLACEBO; PREDNISONE; STEROID;

CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ENCEPHALOMYELITIS; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE DISEASE; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; PROGNOSIS; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; SARCOIDOSIS; VISUAL IMPAIRMENT;

EID: 70349155491     PISSN: 11376627     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. MILLER NR, NEWMAN NJ. Optic Neuritis. En: Wals and Hoyt's-Clinical Neuro-Opthalmology 1999, 5th Edition.
2. MILLER D, MCDONALD I, SMITH K. The diagnosis of multiple sclerosis. En: Compston A, Confavreaux C, Lassmann H et al. McAlpine's Multiple Sclerosis 2006, 4th edition.
3. PURVIN V, KAWASAKI A. Neuro-ophthalmic emergencias for the neurologist. Neurologist 2005; 11: 195-233.
4. KUPERSMITH MJ, ALBAN T, ZEIFFER B, LEFTON D. Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance. Brain 2002; 125: 812-822. (Pubitemid 34279776)
5. OREJA GUEVARA C, NOVAL S. La tomografía de coherencia óptica en la neuritis óptica y esclerosis múltiple. Rev Esp Esclerosis múltiple 2008, Vol I (6): 22-26.
6. COSTELLO F, HODGE W, PAN YI. EGGENBERGER E, COUPLAND S. KARDON RH. Tracking retinal nerve fiber layer loss after optic neuritis: a prospective study using optical coherente tomography. Multiple Esclerosis 2008; 14: 893-905.
7. BECK RW, CLEARY PA, ANDERSON MM JR, KELTNER JL; SHULTS WT, KAUFMAN DI et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992; 326: 581-588.
8. Optic Neuritis Study Group. Neurologic impairment 10 years alter optic neuritis. Arch Neurol 2004; 61: 1386-1389.
9. ATKINS E, BIOUSSE V, NEWMAN NJ. Optic neuritis. Semin Neurol 2007, 27: 211-220.
10. KUPERSMITH MJ, GAL RL, BECK RW, XING D, MILLER N. Visual function at baseline and 1 month in acute optic neuritis: predictors of visual outcome. Neurology 2007; 69: 508-514.
11. BRUSAFERRI F, CANDELISE F. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000; 247: 435-442.
12. RIZZO JF, LESSELL S. Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study. Neurology 1988; 38: 185-714.
13. TINTORÉ M, ROVIRA A, RIO J, NOS C, GRIVÉ E, TÉLLEZ N et al. Is optic neuritis more benign than other first attacks in multiple sclerosis? Ann Neurol 2005; 57: 210-215.
14. The Optic Neuritis Study Trial. Multiple sclerosis risk alter optic neuritis. Final optic neuritis treatment trial follow-up. Arch Neurol 2008; 65 : 727-732.
15. BECK RW, CLEARY PA, TROBE JD, KAUFMAN DI, KUPERSMITH MJ, PATY DW et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Eng J Med 1993; 329: 1764-1769.
16. BREX PA, CICCARELLI O, O'RIORDAN JL, SAILER M, THOMPSON AJ, MILLER DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158-164. (Pubitemid 34438881)
17. JIN YP, DE PEDRO-CUESTA J, HUANG YH, SÖDERSTRÖM, M. Predicting multiple sclerosis at optic neuritis onset. Multiple Sclerosis 2003; 9: 135-141. (Pubitemid 36426987)
18. KHERADVAR A, TABASSI AR, NIKBIN B, KHOSRAVI F, NAROUEYNEJAD M, MORADI B et al. Influence of HLA on progresión of optic neuritis to MS: results of a tour-year follow-up study. Multiple Sclerosis 2004; 10: 526-531.
19. SIMÓ M, BARSI P AND ARÁNYI Z. Predictive role of evoked potencial examinations in patients with clinically isolated optic neuritis in Light of the revised McDonald criteria. Multiple Sclerosis 2008; 14: 472-478.
20. ABOU ZEID N AND BHATTI MT. Acute inflammatory demyelinating optic neuritis. Neurologist 2008;14: 207-223
21. CESTARI DM, METSON RB, CUNNANE ME, FAQUIN WC. Case records of the Massachusetts General Hospital. Case 40-2008. A 26-year-old man with blurred vision. N Engl J Med 2008; 359: 2825-2833.
22. CIKES N, BOSNIC D, SENTIC M. Non-MS autoinmune demyelination. Clin Neurol Neurosur 2008; 110: 905-912.
23. ZAJICEK JP. Neurosarcoidosis. Curr Opin Neurol 2000; 13: 323-325.
24. TENEMBAUM S, CHITNIS T, NESS J, HAHN JS for the Internacional Pediatric MS Study Group) Acute disseminated encephalomyelitis. Neurology 2007; 68 (Suppl2): S23-S36.
25. YOUNG NP, WEINSHENKER BG, LUCCHINETTI CF. Acute disseminated encephalomyelitis: current understanding and controversias. Semin Neurol 2008; 288: 84-94. (Pubitemid 351273086)
26. HARDING AE, SWEENEY MG, MILLER DH, MUMFORD CJ, KELLAR-WOOD H, MENARD D et al. Occurrence of multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain 1992; 115: 978-989.
27. PATO-PATO A, CIMAS-HERNANDO I, LORENZO-GONZÁLEZ JR. Neuropatía óptica de Leber: caso clínico. Rev Neurol 2006; 42: 22-24. (Pubitemid 47378312)
28. KIDD D, BURTON B, PLANT GT, GRAM. EM. Chronic relapsing inflammatory optic neuropathy (CRION). Brain 2003; 126: 276-284.
29. PÉREZ-DÍAZ H, CASADO-CHOCAN JL, UCLES-SÁNCHEZ A, SÁIZ A. Neuropatía óptica inflamatoria recurrente crónica (CRION) sin detección de Acs IgG-NMO. Neurología 2007; 22: 553-555.
30. PITTOCK SJ. Neuromyelitis optica: a new perspectiva. Sem Neurol 2008; 28 (1): 95-104.
31. LENNON VA, WINGERCHUCK DM, KRYZER TJ, PITTOCK SJ, LUCCHINETTI CF, FUJIHARA K et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112. (Pubitemid 39626806)
32. ROEMER SF, PARISI JE, LENNON VA, BENARROCH EE, LASSMANN H, BRUCK W et al. Pattern-specific los of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130: 1194-1205.
33. WINGERCHUK DM, LENNON VA, LUCCHINETTI C, PITTOCK SJ, WEINSHENKER BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-815.
34. VOLPE NJ. The Optic Neuritis Treatment Trial. A definitive answer and profound impact with unexpected results. Arch Ophthalmol 2008, 126: 996-999.
35. CALVETTI O, VIGNAL-CLERMONT C, DREWS-BOTSCH CD, ATKINS EJ, NEWMAN NJ, BIOUSSE V. Prise en charge des névrites optiques isolées en France: enquete auprès des neurologues et des ophtalmologistes. Rev Neurol (Paris) 2008; 164: 233-241.
36. COYLE PK. Early treatment of multiple sclerosis to prevent neurologic damage. Neurology 2008; 71(24 Suppl 3): S3-7.
37. JACOBS LD, BECK RW, SIMON JH, BROWNSCHEIDLE CM, MURREY TJ, SIMONIAN NA et al. Intramuscular interferon beta-1 treatment iniciated during a first demyelinating event in multiple sclerosis. CHAMPS Study group. N Engl J Med 2000; 343: 898-1804
38. CHAMPIONS Study Group. IM interferon beta-1 delays definite multiple sclerosis 5 years alter a first demyelinating event. Neurology 2006; 66: 678-684. (Pubitemid 43739821)
39. COMI G, FILIPPI M, BARKHOF, DURELLI L, EDAN G, FERNÁNDEZ O et al. Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study (ETOMS). Lancet 2001; 357: 1576-1582.
40. KAPPOS L, POLMAN CH, FREEDMAN MS, EDAN G, HARTUNG HP, MILLER DH et al. Treatment with interferon beta-1b delays conversión to clinically definite and MCDonald MS in patients with clinically isolated síndromes. Neurology 2006; 67: 1242-1249.